← Dashboard
Stock
SRPT
Sarepta Therapeutics, Inc.Health CareBiotechnologyLatest close $175 of 27 marquee funds currently hold3 CUSIPs mapped
Current holders
5
27 funds tracked
Ever held
12
Current + past
New this quarter
0
Exited this quarter
1
Marquee-fund ownership over time
Aug 14, 2013Nov 12, 2021May 15, 2025May 15, 2026
Now
8
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q2 2021 | 21Q | $76 | $17 | -78% |
| Renaissance Technologies re-entered | Q3 2024(8Q snapshot) | 7Q | $125 | $17 | -86% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $133 | $17 | -87% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $17 | — |
| AQR Capital Management | Q1 2025(8Q snapshot) | 5Q | $108 | $17 | -84% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management 3× in & out | Q1 2026 | Q2 2026 | → $18 | -2% |
| Two Sigma Investments 2× in & out | Q3 2025 | Q4 2025 | — | +0% |
| Millennium Management 3× in & out | Q3 2025 | Q4 2025 | — | +0% |
| Soros Fund Management | Q4 2024 | Q2 2025 | → $35 | -68% |
| Duquesne Family Office | Q3 2020 | Q4 2020 | → $140 | -11% |
| Coatue Management | Q1 2020 | Q2 2020 | → $141 | +13% |
| Viking Global Investors | Q3 2013 | Q4 2013 | → $14 | -56% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Sarepta Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
8
Filings · last 90d
17
Total on file
447
Recent SEC buffer
Most recent
Jun 5, 2026
30d / 90d windows measured from Jun 5, 2026 — the most recent Form 4 on file — not from today.
- Form 40001193125-26-260263Jun 5, 2026
- Form 40001193125-26-260261Jun 5, 2026
- Form 40001193125-26-260259Jun 5, 2026
- Form 40001193125-26-260257Jun 5, 2026
- Form 40001193125-26-260255Jun 5, 2026
- Form 40001193125-26-260250Jun 5, 2026
- Form 40001193125-26-260246Jun 5, 2026
- Form 40001193125-26-260245Jun 5, 2026
- Form 40001193125-26-106710Mar 13, 2026
- Form 40001193125-26-106706Mar 13, 2026
- Form 40001193125-26-106703Mar 13, 2026
- Form 40001193125-26-106701Mar 13, 2026
- Form 40001193125-26-106697Mar 13, 2026
- Form 40001193125-26-102710Mar 11, 2026
- Form 40001193125-26-102708Mar 11, 2026
Showing 15 of 447 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · Sarepta Therapeutics, Inc.Annual figures sourced directly from Sarepta Therapeutics, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$2.2B
FY2025+450% YoY
Net income
-$713.41M
FY2025-500%+ YoY
EPS (diluted)
$-7.13
FY2025-500%+ YoY
Free cash flow(?)
-$307.45M
FY2025+10% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Sarepta Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 4, 2026
- 8-KMaterial eventMay 6, 2026
- 10-QQuarterly reportMay 6, 2026
- DEF 14AProxy statementApr 24, 2026
- 10-KAnnual reportMar 2, 2026
- 8-KMaterial eventFeb 25, 2026
- 8-KMaterial eventFeb 25, 2026
- 8-KMaterial eventJan 12, 2026
- 8-KMaterial eventDec 19, 2025
- 8-KMaterial eventDec 11, 2025
- 8-KMaterial eventDec 8, 2025
- 10-QQuarterly reportNov 6, 2025
- 8-KMaterial eventNov 3, 2025
- 8-KMaterial eventAug 29, 2025
- 8-KMaterial eventAug 21, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | Q2 2026 | $18 | $18 | -2% |
| Bridgewater Associates | Q4 2025 | open | $18 | $16 | -10% |
| Two Sigma Investments | Q3 2025 | Q4 2025 | $0.00 | — | +0% |
| D.E. Shaw | Q3 2025 | open | $0.00 | — | +0% |
| Millennium Management | Q3 2025 | Q4 2025 | $0.00 | — | +0% |
| Renaissance Technologies | Q3 2025 | open | $20 | $17 | -17% |
| AQR Capital Management | Q1 2025 | open | $108 | $17 | -84% |
| Point72 Asset Management | Q1 2025 | Q4 2025 | $0.00 | — | +0% |
| Bridgewater Associates | Q1 2025 | Q3 2025 | $109 | $20 | -81% |
| Soros Fund Management | Q4 2024 | Q2 2025 | $109 | $35 | -68% |
| Millennium Management | Q4 2024 | Q2 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | open | $133 | $17 | -87% |
| Two Sigma Investments | Q3 2024 | open | $133 | $17 | -87% |
| D.E. Shaw | Q3 2024 | Q1 2025 | $0.00 | — | +0% |
| D.E. Shaw | Q3 2024 | open | $133 | $17 | -87% |
| Millennium Management | Q3 2024 | open | $133 | $17 | -87% |
| Point72 Asset Management | Q3 2024 | Q1 2025 | $133 | $108 | -19% |
| Renaissance Technologies | Q3 2024 | Q1 2025 | $125 | $109 | -13% |
| Bridgewater Associates | Q2 2022 | Q3 2024 | $66 | $133 | +102% |
| Bridgewater Associates | Q2 2021 | Q4 2021 | $76 | $85 | +12% |
| Duquesne Family Office | Q3 2020 | Q4 2020 | $157 | $140 | -11% |
| Coatue Management | Q1 2020 | Q2 2020 | $125 | $141 | +13% |
| Viking Global Investors | Q3 2013 | Q4 2013 | $33 | $14 | -56% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.